Full coverage: Donald Trump

Multinationals led by pharmaceutical manufacturers have long used intangible assets and transfer pricing to shift profits to Ireland. Could the same moves work in reverse to reduce exposure to tariffs?

Ireland will become utterly isolated should it choose to opt out of European defence integration as the Donald Trump-led America continues to align closer with Russia over its traditional Western allies.

Stocks took a tumble last week. For the first time in a long time, the pessimists had the upper hand. But longer term for investors, nothing has changed. They still have little to fear from The Donald.

Social media companies will hope their close relationship with US President Donald Trump will ease the burden of regulation in the likes of Europe and the UK. But parent groups may complicate that.

This week has seen the US set the European agenda, giving its Nato allies a choice between a real war or a trade war.

Some field staff employed by Goal, Concern, Trócaire, and Self Help Africa are paid with funding from the American agency targeted by Donald Trump and Elon Musk.

Tech and pharma firms woke up from the presidential inauguration night with no tariffs or tax moves affecting their Irish structures. The threats are real, however.

Deadlines are looming on key rules deciding how American multinationals’ profits are taxed in Ireland. Trump and his supporters in Congress have yet to decide how much they will let away this time.

Labour and the incoming Irish government will have to place a significant emphasis on US relations in the new year with both facing threats from a protectionist Trump regime.

America has spoken. The world is now trying to make sense of what it means. To unreal Donald Trump’s success, Sam Smyth is joined in New York by defence lawyer Barry Scheck, author and one-time New York gossip columnist Joanna Molloy, and Jamie Smyth, US energy editor of The Financial Times.